Anastasia Zekeridou, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated panels and methodology boost the accuracy and efficiency of testing for three autoimmune neurology biomarkers. Early diagnosis is key to managing debilitating conditions associated with these antibodies.


(00:32)
 Could you please give our listeners an overview of your role at Mayo Clinic?

 

(01:22)
 What updates are happening in our laboratory to increase specificity when we receive a patient's serum and CSF for most of the CNS evaluations?

 

(03:48)
 Why are these updates and additions important in the larger disease state?

(06:16)
 Could you expound upon the relationship between the clinical practice and the lab?

 

(08:32)
 What do these changes mean for patient care?

 

(10:27)
 What about the inclusion of AMPA in the pediatric evaluation, and the inclusion of IgLON5 with autoimmune axonal?

 

(12:58)
 How does your lab discern when it's time to add a biomarker?

 

(15:44)
 What are you most excited about?